Arvinas Inc. Feb 20, 2024, 7:00 AM ET –ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2(LRRK2) – ...

maraviroc Selzentry 150mg, 300mg tabs Adults: Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer): 150mg twice daily. Noninteracting concomitant drugs, including ...

In non-human primates, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90%. The Phase 1 clinical trial of ARV-102 is enrolling healthy volunteers ...

Further complicating dosing during travel, antiretroviral drugs like rilpivirine, efavirenz, tenofovir, elvitegravir, and boosted protease inhibitors, should be taken with food—and that can be a ...

The Phase 1 open-label, dose-escalation clinical trial will assess the safety, tolerability, and pharmacokinetics of ARV-110 and is expected to enroll approximately 28-36 patients with progressive ...

Weight-based user-friendly tables have been recently developed by the WHO [7] to optimise ARV dosing in children in resource-limited settings. Several combinations of individual NRTIs are possible.